SCHEMBL5887265

SCHEMBL5887265

COc1ccc(C2=C(c3ccc(Oc4ccccc4)cc3)C[CH]C(Cl)=C2Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.49
ESR1 P03372 2/20 0.42
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA4 P22748 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
PTGS1 P23219 2/20 0.37
BTK Q06187 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GSK3B P49841 1/20 0.36
GSTP1 P09211 1/20 0.36
MCL1 Q07820 1/20 0.36
HSP90AA1 P07900 2/20 0.36
HSP90AB1 P08238 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887214 0.80 RAD51 (0.46) ESR1
SCHEMBL5886915 0.78 LTA4H (0.49) LTA4HESR1MAPTMEN1KMT2A
SCHEMBL5887140 0.74 LTA4H (0.44) LTA4HESR1MAPTMEN1KMT2A
SCHEMBL15722134 0.72 LTA4H (0.86) LTA4HMAPTMEN1KMT2ACA4
SCHEMBL17283659 0.70 LTA4H (1.00) LTA4HMAPTMEN1KMT2ACA4
SCHEMBL491503 0.70 LTA4H (1.00) LTA4HMAPTMEN1KMT2ACA4
SCHEMBL5887406 0.69 PTGS1 (0.42) ESR1PTGS1NPC1RAB9ASMN1; SMN2
SCHEMBL5886946 0.69 LTA4H (0.50) LTA4HMAPTMEN1KMT2ACA4
SCHEMBL4307648 0.68 LTA4H (0.77) LTA4HMAPTMEN1KMT2ACA4
SCHEMBL20694283 0.68 LTA4H (0.77) LTA4HMAPTMEN1KMT2ACA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R LTA4H 3106/4885ESR1 850/4885MAPT 2577/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R LTA4H 3360/4885ESR1 202/4885MAPT 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.